Literature DB >> 15208503

Whole-body biodistribution and radiation dosimetry estimates for the PET dopamine transporter probe 18F-FECNT in non-human primates.

Dnyanesh N Tipre1, Masahiro Fujita, Frederick T Chin, Nicholas Seneca, Douglas Vines, Jeih-San Liow, Victor W Pike, Robert B Innis.   

Abstract

BACKGROUND AND AIM: 2 beta-Carbomethoxy-3-(4-chlorophenyl)-8-(2-[18F]fluoroethyl)nortropane (18F-FECNT) is a selective radioligand for the in vivo quantification of dopamine transporters by using positron emission tomography. The aim of the current study was to quantify the distribution of radioactivity in three rhesus monkeys after the injection of approximately 185 MBq (5 mCi) of 18F-FECNT.
METHOD: Whole-body images were acquired at 23-30 time points for a total of 220 min following injection of the radioligand. Source organs were identified at each time point from planar images.
RESULTS: The peak activities in planar images in the six identified source organs (expressed as per cent injected dose (%ID)) were lungs (16.5%ID at 2 min), kidneys (12.5%ID at 3 min), brain (9.5%ID at 6 min), liver (7.5%ID at 3 min), red bone marrow (3.5%ID at 12 min), and urinary bladder (2%ID at 98 min). Radiation absorbed doses were calculated using the gastrointestinal tract model in two ways: (1) assuming no urine voiding, and (2) using a dynamic bladder model with voiding intervals of 2.4 and 4.8 h. Using the gastrointestinal tract model and dynamic bladder model with a voiding interval 4.8 h, the three organs with highest exposure (in mu Gy.MBq(-1) (mrad.mCi(-1)) were kidneys 75.68 (280), lungs 44.86 (166) and urinary bladder 58.38 (216). Effective doses estimated with and without urine voiding were in the range 21.35-22.70 mu Gy.MBq(-1) (79-84 mrad.mCi(-1)).
CONCLUSION: The estimated radiation burden of 18F-FECNT is relatively modest and would allow multiple scans per research subject per year.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15208503      PMCID: PMC4133981          DOI: 10.1097/01.mnm.0000133074.64669.60

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  18 in total

1.  Biodistribution and radiation dosimetry of the dopamine transporter ligand.

Authors:  T A Deterding; J R Votaw; C K Wang; D Eshima; L Eshima; R Keil; E Malveaux; C D Kilts; M M Goodman; J M Hoffman
Journal:  J Nucl Med       Date:  2001-02       Impact factor: 10.057

Review 2.  The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates.

Authors:  L L Howell; K M Wilcox
Journal:  J Pharmacol Exp Ther       Date:  2001-07       Impact factor: 4.030

Review 3.  Mesocorticolimbic dopaminergic network: functional and regulatory roles.

Authors:  M Le Moal; H Simon
Journal:  Physiol Rev       Date:  1991-01       Impact factor: 37.312

4.  Radiological protection and safety in medicine. A report of the International Commission on Radiological Protection.

Authors: 
Journal:  Ann ICRP       Date:  1996

5.  Dose to the fetus from radionuclides in the bladder.

Authors:  R J Cloutier; S A Smith; E E Watson; W S Snyder; G G Warner
Journal:  Health Phys       Date:  1973-08       Impact factor: 1.316

Review 6.  PET evaluation of the dopamine system of the human brain.

Authors:  N D Volkow; J S Fowler; S J Gatley; J Logan; G J Wang; Y S Ding; S Dewey
Journal:  J Nucl Med       Date:  1996-07       Impact factor: 10.057

Review 7.  The pharmacology of Parkinson's disease therapy: an update.

Authors:  I J Kopin
Journal:  Annu Rev Pharmacol Toxicol       Date:  1993       Impact factor: 13.820

Review 8.  The dopamine transporter: a crucial component regulating dopamine transmission.

Authors:  M Jaber; S Jones; B Giros; M G Caron
Journal:  Mov Disord       Date:  1997-09       Impact factor: 10.338

Review 9.  The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD).

Authors:  Bertha K Madras; Gregory M Miller; Alan J Fischman
Journal:  Behav Brain Res       Date:  2002-03-10       Impact factor: 3.332

10.  Fluorine-18-FPCT: a PET radiotracer for imaging dopamine transporters.

Authors:  M M Goodman; R Keil; T M Shoup; D Eshima; L Eshima; C Kilts; J Votaw; V M Camp; D Votaw; E Smith; M P Kung; E Malveaux; R Watts; M Huerkamp; D Wu; E Garcia; J M Hoffman
Journal:  J Nucl Med       Date:  1997-01       Impact factor: 10.057

View more
  5 in total

1.  Suggested pathway to assess radiation safety of 11C-labeled PET tracers for first-in-human studies.

Authors:  Paolo Zanotti-Fregonara; Robert B Innis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-08       Impact factor: 9.236

2.  Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [18F]SPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis.

Authors:  David R Sprague; Frederick T Chin; Jeih-San Liow; Masahiro Fujita; H Donald Burns; Richard Hargreaves; James B Stubbs; Victor W Pike; Robert B Innis; P David Mozley
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

3.  Synthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emission tomography.

Authors:  Jeffrey S Stehouwer; Lauryn M Daniel; Ping Chen; Ronald J Voll; Larry Williams; Susan J Plott; John R Votaw; Michael J Owens; Leonard Howell; Mark M Goodman
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

4.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

5.  Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys.

Authors:  Ya-Yao Huang; Kuo-Hsing Ma; Ta-Wei Tseng; Ta-Kai Chou; Hanna Ng; Jon C Mirsalis; Ying-Kai Fu; Tieh-Chi Chu; Wen-Sheng Huang; Chyng-Yann Shiue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-10       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.